🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Reminder we are hosting a webinar with PPMD today at 1:00 p.m. ET to discuss the latest updates on our deramiocel program. $CAPR #PPMD #DMD #deramiocel <<<Click to register parentprojectmd-org.zoom.us/webinar/regist…>>>

Capricor is delighted to be presenting at the 2025 Leerink Global Healthcare Conference in Miami, FL. Our presentation will be on Wednesday, March 12 at 1:00 p.m. ET To register for the webcast, click here: wsw.com/webcast/leerin… $CAPR #deramiocel #DMD

On March 19, 2025, Capricor will release our fourth quarter and full year 2024 financial results and host our conference call at 4:30 p.m. ET $CAPR <<<Click to register for the webcast bit.ly/4kG2p0c>>>

Don't miss Capricor's presentation today, March 12 at 1:00 p.m. ET. We will be present at the 2025 Leerink Global Healthcare Conference in Miami, FL. To register for the webcast, click here: wsw.com/webcast/leerin… $CAPR #deramiocel #DMD

The 2025 Muscular Dystrophy Association (MDA) Conference starts this weekend in Dallas, Texas! MDA brings together clinicians, researchers, and industry leaders to share the latest breakthroughs in DMD and other neuromuscular diseases. Capricor will be featured in the

Capricor is pleased to share the data from our late-breaking poster which was showcased over the weekend at the 2025 MDA Conference in Dallas. <<<Click the link to read the press release bit.ly/4iinMmP>>> #MDA2025 $CAPR #Neuromuscular #MuscularDystrophy #DMD #deramiocel

Capricor just announced our fourth quarter and full year 2024 financial results and corporate update. <<<Click to read the press release bit.ly/3E0uyyA>>> $CAPR

Don’t forget to tune into our quarterly conference call and webcast starting at 4:30 p.m. ET today. <<<Click the link to access the webcast bit.ly/4kG2p0c>>> #CAPR

Capricor will be presenting at the 2025 Piper Sandler Virtual Cardio Day on April 2 in a fireside chat starting at 12:00 p.m. ET to discuss the latest updates on our deramiocel program for the treatment of Duchenne muscular dystrophy (DMD). $CAPR #DMD #deramiocel <<<Click here

Capricor is pleased to announce the successful completion of our mid-cycle review meeting with the FDA, along with plans for an upcoming advisory committee meeting, as we continue to advance our Biologics License Application (BLA) for deramiocel for the treatment of Duchenne

On May 13, 2025, Capricor will release our first quarter 2025 financial results and host our conference call at 4:30 p.m. ET <<<Click to register for the webcast bit.ly/4jOaa3E>>> $CAPR #Deramiocel #DMD #RareDisease

We are pleased to announce the appointment of Dr. Michael Binks as our Chief Medical Officer. Dr. Binks joins Capricor with over 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors.<<<Click to

Capricor just announced our first quarter 2025 financial results and corporate update <<<Click to read the full announcement bit.ly/3S21Tg4>>> $CAPR #RareDisease

Capricor’s quarterly conference call and webcast is starting at 4:30 p.m. ET today. <<<Click the link to access the webcast bit.ly/4jOaa3E>>> $CAPR #RareDisease

Capricor will be presenting today at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ starting at 11:00 a.m. ET to discuss the latest updates on our deramiocel program for the treatment of DMD. $CAPR <<<Click here to listen to the webcast>>>

Capricor is pleased to announce key regulatory updates for our Duchenne muscular dystrophy program.<<<Click to read the full release bit.ly/3SI5LDo>>> $CAPR #Deramiocel #DMD #RareDisease

Capricor is pleased to announce that the U.S. FDA has granted Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening our focus in neuromuscular diseases. Read the full press release: bit.ly/3SV7Uf2 $CAPR #Deramiocel #RareDisease

Capricor is very pleased to announce positive four-year data from our HOPE-2 OLE study of Deramiocel in DMD which is being presented at the 2025 PPMD Annual Conference taking place this weekend in Las Vegas! Click to read the full announcement. >>>bit.ly/4ncpyJ3>>>

Cardiac Complications of Duchenne Muscular Dystrophy medpagetoday.com/spotlight/dmd/…

Capricor is pleased to provide a regulatory update for its DMD program—Deramiocel remains under Priority Review with FDA target action date set for August 31, 2025. Read more: bit.ly/3G28YuN $CAPR #Deramiocel #DMD #RareDisease